Labviva Showcases Advanced AI Procurement Tools at the R&D Procurement and Sourcing in Pharma Summit 2025

BOSTON, June 19, 2025 (GLOBE NEWSWIRE) — Labviva, the leading AI procurement platform for life sciences, today announced its plans to demonstrate how pharmaceutical and biotech companies can leverage AI for laboratory procurement to drive cost and resource efficiencies and accelerate the pace of scientific innovation. The company will showcase its purchasing platform and inventory management solution (IMS) and plans to debut a new AI solution at the R&D Procurement & Sourcing in Pharma Summit, located at the Hilton Boston Logan Airport on June 24-26.
Co-presenting panel on 'Modernizing Inventory Management: How Neutral Models Are Enabling Smarter Lab Operations'
This panel will focus on lessons learned, change leadership, and value delivered through a vendor-neutral approach to inventory management. It will also highlight: How Takeda modernized its lab supply strategy with a vendor-agnostic, data-driven approach to inventory management
How a neutral model improved visibility, reduced waste, and gave Takeda more control over their supply needs
How Boston Lab Services and Labviva partnered to deliver automation, flexibility, and operational excellence
Actionable insights for transforming procurement from a cost center into a strategic R&D enabler
The talk will take place at the R&D Procurement & Sourcing in Pharma Summit at 10:00 a.m. on June 26. It will be moderated by Kleida Martiro, Partner at Glasswing Ventures and panelists include Hillary Ferrer, R&D Operations at Takeda, Andrew Petterelli, Procurement at Takeda, Elden Lainez, CEO of Boston Lab Services and Nick Rioux, CTO of Labviva.
Labviva's R&D Procurement Cocktail Reception
Show attendees and members of the press can RSVP for Labviva's cocktail event which takes place at the Hilton Boston Logan Airport, One Hotel Dr, Boston, MA 02128, on June 24th from 5:00pm-6:00pm.
'At the R&D Procurement & Sourcing in Pharma Summit, we plan to demonstrate the value of modernizing research procurement processes using AI automation,' said Siamak Baharloo, CEO of Labviva. 'In an era of tariffs and trade wars, compliance and efficiency are king. And with Labviva, pharmaceutical procurement teams enjoy improved transparency, diverse supplier access, broad product and pricing options, and the inventory controls they need to ensure compliance, supply chain security, and mass efficiencies while maintaining complete control of their data.'
To schedule a meeting or press interview with Labviva, please contact Jennifer Olszewski at [email protected]
About Labviva
Labviva connects researchers with suppliers of reagents, chemicals, and instrumentation in an intuitive, user-friendly platform that supports the priorities of scientists while staying compliant with purchasing rules. Suppliers can easily manage the content of their products, and products are mapped into scientific applications, techniques and protocols. To learn more about how Labviva accelerates the science of life, visit us at www.labviva.com.
Media Contacts:Jennifer OlszewskiLabviva917-445-4454
[email protected]

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

9 hours ago

• Yahoo

Oracle Full Year 2025 Earnings: In Line With Expectations

Revenue: US$57.4b (up 8.4% from FY 2024). Net income: US$12.4b (up 19% from FY 2024). Profit margin: 22% (up from 20% in FY 2024). The increase in margin was driven by higher revenue. EPS: US$4.46 (up from US$3.82 in FY 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. The primary driver behind last 12 months revenue was the Cloud and License segment contributing a total revenue of US$49.2b (86% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to US$9.86b (35% of total expenses). Explore how ORCL's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Software industry in the US. Performance of the American Software industry. The company's shares are down 4.7% from a week ago. Before you take the next step you should know about the 2 warning signs for Oracle that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Yahoo

19 hours ago

• Yahoo

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Forbes

a day ago

• Forbes

This Rideable Robot Is A Man-Made Horse Powered By Hydrogen

It had to happen. One day, humans had to attempt to make their own horse. Or a machine as close as can be to a rideable Rottweiler. Boasting the combined attributes of a horse, a mountain lion and a motorcycle, here it is—the Kawasaki Corleo concept. That's right, it'll be a while before you can actually buy one. Check out the video below. According to the company, one day deep in the R&D department, someone dared to ask, 'What if we put legs on an all-terrain vehicle?' So, working outside of their comfort zone, engineers created the Corleo. The resulting vehicle incorporates the company's vision of mobility in 2050, where instinct, technology and the natural environment move in sync. Or at least, that's what Kawasaki Heavy Industries says. Corleo is a 4-legged rideable robot targeting a 2050 future Unveiled recently at the Expo 2025 Osaka in Japan, the Corleo is a revolutionary off-road personal mobility vehicle—a rideable robot propelled by four legs and powered by an engine fueled with hydrogen. While Kawasaki did actually unveil this real-life concept, it was the brand's computer-generated video that has generated intense interest online. Making the Corleo look like a hoot to ride, the imagery portrays a rideable four-legged robot that comes across as an advanced version of Boston Dynamics' Spot —the dog-like robot mixed with the fun of Luke Skywalker's Landspeeder cruiser. Having racked up over 1.1 million views so far, the CGI video shows the Corleo galloping through a thick forest, frolicking across a field, leaping across a small gorge and trotting across a snowy outcrop in a landscape mimicking scenes from Lord of the Rings. Corleo employs independently articulating legs As far as actual riding goes, Kawasaki says that the Corleo mimics the responsive feel of an ATV or even a motorcycle, but instead of using wheels, it employs independently articulating legs with swing arms that absorb impact and shocks and adapt to uneven terrain. Each leg is fitted with a hoof made from slip-resistant rubber, split left-to-right to adapt to different surfaces like grass, gravel, and rock. This four-legged construction maintains balance and stability as it keeps the rider's body in an upright forward-looking posture, even when climbing steps. Corleo employs some clever design ideas, including independent legs, a hydrogen engine and steering through weight shifts using sensors in the stirrups and handlebars. The rear leg unit can swing up and down independently from the front leg unit, allowing it to absorb shocks during walking and running. A 150cc hydrogen engine produces electricity to propel the leg-mounted drive units, with rear-mounted hydrogen canisters supplying fuel to deliver low emissions and silent operation. An onboard GPS navigation screen guides riders by mapping a path up or down a hill, while also ensuring the rider's center of gravity, and hydrogen fuel levels. "While preserving the joy of riding, the vehicle continually monitors the rider's movements to achieve a reassuring sense of unity between human and machine," Kawasaki said.